Palatin Technologies Inc.
ASE:PTN 10:00:47 AM EDT
| Market Cap (Intraday) | 18.76M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.61 |
| 50-Day MA | $2.09 |
| 200-Day MA | $2.61 |
Palatin Technologies Inc. Stock, ASE:PTN
Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, New Jersey 08512
United States of America
Phone: +1.609.495.2200
Number of Employees: 33
Description
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.